News & Events about Magenta Therapeutics Inc.
Thinking about buying stock in Genetic Technologies, Heart Test Laboratories, Magenta Therapeutics, Carvana, or C3.ai? Thinking about buying stock in Genetic Technologies, Heart Test Laboratories, Magenta Therapeutics, Carvana, or C3.ai? PR Newswire NEW YORK, Feb. 3, 2023 NEW YORK, Feb. 3, 2023...
Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities Plan to Dose Additional Participants in Cohort 3 per Clinical Trial Protocol CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announces that, per the clinical trial ...
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics(Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at ...
Globe Newswire
3 months ago
New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; clinical trial has progressed into the third dose escalation cohort; oral presentation of clinical ...
Globe Newswire
3 months ago
Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical data supporting proof-of-mechanism Poster presentation of data from a MGTA-117 non-human primate study that has provided predictive modeling of biologic activity in the ongoing Phase 1/2 dose ...